Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats.
Within the past 2 years, a putative causal relationship has been reported between vaccination against rabies and the development of fibrosarcomas at injection sites in cats. A retrospective study was undertaken, involving 345 cats with fibrosarcomas diagnosed between January 1991 and May 1992, to assess the causal hypothesis. Cats with fibrosarcomas developing at body locations where vaccines are typically administered (n = 185) were compared with controls (n = 160) having fibrosarcomas at locations not typically used for vaccination. In cats receiving FeLV vaccination within 2 years of tumorigenesis, the time between vaccination and tumor development was significantly (P = 0.005) shorter for tumors developing at sites where vaccines are typically administered than for tumors at other sites. Univariate analysis, adjusted for age, revealed associations between FeLV vaccination (odds ratio [OR] = 2.82; 95% confidence interval [CI] = 1.54 to 5.15), rabies vaccination at the cervical/interscapular region (OR = 2.09; 95% CI = 1.01 to 4.31), and rabies vaccination at the femoral region (OR = 1.83; 95% CI = 0.65 to 5.10) with fibrosarcoma development at the vaccination site within 1 year of vaccination. Multivariate analysis, adjusted for age and other vaccines, also revealed increased risks after FeLV (OR = 5.49; 95% CI = 1.98 to 15.24) and rabies (OR = 1.99; 95% CI = 0.72 to 5.54) vaccination.(ABSTRACT TRUNCATED AT 250 WORDS)
Kass
P H
PH
Department of Epidemiology and Preventive Medicine, School of Veterinary Medicine, University of California, Davis 95616-8735.
Barnes
W G
WG
Spangler
W L
WL
Chomel
B B
BB
Culbertson
M R
MR
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects; D000367:Age Factors; D000818:Animals; D002140:California / Q000453:epidemiology; D016022:Case-Control Studies; D002371:Cat Diseases / Q000453:epidemiology / Q000209:etiology*; D002415:Cats; D015331:Cohort Studies; D005260:Female; D005354:Fibrosarcoma / Q000453:epidemiology / Q000209:etiology / Q000662:veterinary*; D006254:Hawaii / Q000453:epidemiology; D015994:Incidence; D007273:Injections, Intramuscular / Q000009:adverse effects / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000009:adverse effects / Q000662:veterinary; D005256:Leukemia Virus, Feline / Q000276:immunology; D008297:Male; D015999:Multivariate Analysis; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D015682:Retroviridae Proteins, Oncogenic / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D012983:Soft Tissue Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000662:veterinary*; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects
D000276:Adjuvants, Immunologic; D011819:Rabies Vaccines; D015682:Retroviridae Proteins, Oncogenic; D014765:Viral Vaccines; C045569:feline leukemia virus vaccine